Triomics
Category: AI in Healthcare
Oncology-specific AI platform that automates clinical trial matching, visit preparation, and cancer registry abstraction for cancer centers. Triomics was founded in 2021. The company is led by Sarim Khan. Based in New York, NY. Team size: 51-200. Total funding raised: $38.6M. Latest round: Series B. Key investors include Battery Ventures; Lightspeed; Nexus Venture Partners; General Catalyst; Y Combinator; Progression.Fund.
- Founded
- 2021
- Headquarters
- New York, NY
- Team size
- 51-200
- Total funding
- $38.6M
Value proposition
Triomics replaces manual chart review with task-driven AI agents that read the full longitudinal oncology record and produce structured, cited, auditable outputs directly inside clinical workflows (EHRs like Epic).
Products and solutions
PRISM (clinical trial matching); Symphony (visit preparation & pre-charting); Harmony (cancer registry & quality improvement); OncoLLM (proprietary oncology LLM family, 8 models from 3B to 72B parameters)
Unique value
Oncology-specific AI (OncoLLM) trained on oncology data, not generic medical AI — reads entire multi-year patient records (hundreds of pages), provides cited/auditable outputs, integrates natively with Epic and other oncology EHRs
Target customer
NCI-designated cancer centers, academic medical centers, community oncology practices, and life sciences organizations
Industries served
Healthcare / Oncology / Cancer Research / Life Sciences
Technology advantage
OncoLLM — a proprietary family of 8 oncology-tuned LLMs (3B to 72B parameters) that function in an agentic manner to reason across the full patient record; published accuracy of 95% in clinical trial matching; ASCO 2025 abstract results showing 30% lift in trial accruals and 40% more matches generated
How they differentiate
Unlike generic AI scribes (Abridge, Nuance) that focus on patient-doctor conversation documentation, Triomics is purpose-built for oncology — reading the full longitudinal chart (not just one visit), trained specifically on oncology data, and focused on trial matching, visit prep, and registry abstraction rather than ambient scribing
Main competitors
Abridge; Microsoft Nuance (DAX); Manifold
Key partnerships
Memorial Sloan Kettering Cancer Center (MSK); Yale Cancer Center; Mount Sinai Tisch Cancer Center; Savista (automated cancer registry solution); Medical College of Wisconsin; Epic App Marketplace approved
Notable customers
Memorial Sloan Kettering Cancer Center (MSK); Yale Cancer Center; Mount Sinai Tisch Cancer Center; Medical College of Wisconsin Cancer Center
Major milestones
2021: Founded, YC W21 batch; 2024: $15M Series A; Oct 2025: MSK partnership announced; Nov 2025: Savista partnership for automated cancer registry; Jan 2026: Mount Sinai launches AI trial matching with Triomics; May 2026: $22M Series B led by Battery Ventures
Growth metrics
4x enterprise customer base growth YoY; 10x ARR increase over past year; 120,000+ charts read monthly; 65,000+ patients screened for trials monthly; 70% faster chart review; 30% lift in trial accruals; 80% reduction in new patient visit prep time
Market positioning
Leading oncology-specific AI platform for enterprise cancer centers; 4 of top 10 U.S. cancer centers (U.S. News ranked) are customers; 10+ NCI-designated cancer centers; 4x enterprise customer base growth YoY; 10x ARR increase over past year
Geographic focus
United States (primary); expanding across top academic and community oncology practices
About Sarim Khan
Ex-MIT biotech researcher (tissue engineering); IIT Roorkee Chemical Engineering
Latest news about Triomics
More AI in Healthcare companies
Official website: https://triomics.com
